NASDAQ
134.50USD
+0.27 (+0.20%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
8.3B
P/E
—
EPS
—
Beta
0.33
52W range
34.34-134.58
Day range
134.25–134.58
Open
134.33
Prev close
134.23
Volume
848K
Avg volume
2.6M
Dividend
0.00
IPO
2023-07-14
https://www.zacks.com/stock/news/2970197/abbv-stock-dips-4-despite-robust-q2-buy-the-dip-or-stay-cautious?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2970197 · 8/6/2026+0.50
https://www.fool.com/investing/2026/07/25/why-wall-street-cant-get-enough-of-this-dividend-k/ · 7/25/2026+0.60
https://www.fool.com/investing/2026/07/19/how-will-abbvies-109-billion-acquisition-of-apogee/ · 7/20/2026+0.60
https://www.zacks.com/stock/news/2954089/should-you-buy-sell-or-hold-abbv-stock-after-its-9-ytd-rise?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2954089 · 7/15/2026+0.60
https://www.fool.com/investing/2026/07/11/abbvie-is-already-a-dividend-king-heres-why-the-10/ · 7/12/2026+0.60
https://www.gurufocus.com/news/8946447/are-avb-lpro-apge-tmhc-obtaining-fair-deals-for-their-shareholders · 7/7/2026-0.20
https://www.globenewswire.com/news-release/2026/07/02/3321186/884/en/shareholder-alert-ademi-llp-investigates-whether-bio-techne-corporation-is-obtaining-a-fair-price-for-public-shareholders.html · 7/2/2026-0.40
https://seekingalpha.com/article/4919340-abbvie-apogee-deal-just-widened-an-already-dominant-moat · 7/2/2026+0.90
https://www.fool.com/investing/2026/06/22/why-abbvie-stock-is-up-today/ · 6/23/2026+1.00
https://www.benzinga.com/trading-ideas/movers/26/06/60007934/why-sagtec-global-shares-are-trading-higher-by-around-76-here-are-20-stocks-moving-premarket · 6/22/2026+1.00
https://www.marketbeat.com/instant-alerts/apogee-therapeutics-maps-phase-3-push-for-zumilokibart-backed-by-blackstone-funding-2026-06-10/ · 6/11/2026+0.90
https://seekingalpha.com/article/4909424-apogee-therapeutics-inc-apge-discusses-positive-part-b-results-from-phase-2-apex-trial-of · 6/1/2026+1.00
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
